for people ages 18 years and up (full criteria)
at San Francisco, California
study started
estimated completion
Principal Investigator
by Nicholas Fidelman
Headshot of Nicholas Fidelman
Nicholas Fidelman



This is a phase I dose escalation study (3+3 design) with a dose expansion arm (12 patients) designed to evaluate safety of the combination of Tas-102 and radioembolization using Yttrium-90 (90Y) resin microspheres for patients with chemotherapy-refractory liver-dominant chemotherapy-refractory metastatic colorectal cancer (mCRC).

Official Title

Phase I Study of Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases


Randomized studies have demonstrated that Tas-102 has single agent activity against chemotherapy refractory colorectal cancer. A recent pre-clinical study has shown that Tas-102 may have activity as a radiation sensitizer in bladder cancer cell lines. Benefit of single agent Tas-102 against chemotherapy refractory colon cancer and the drug's promise a radiosensitizer make Tas-102 a potential candidate drug for testing in combination with radioembolization using Yttrium-90 resin microspheres in patients with liver-dominant chemotherapy-refractory mCRC. This is a phase I dose escalation study with a dose expansion arm designed to evaluate safety of the combination of Tas-102 and radioembolization using 90Y resin microspheres for patients with chemotherapy-refractory colon or rectal adenocarcinoma metastatic to the liver.


Colon Cancer Rectal Cancer Liver Metastases radioembolization Yttrium-90 90Y Resin microspheres Tas-102 Lonsurf SIR-Sphere Neoplasm Metastasis Liver Neoplasms Tas-102 and radioembolization


You can join if…

Open to people ages 18 years and up

  1. Male or female, 18 years of age or older, and of any ethnic or racial group.
  2. Diagnosis of unresectable metastatic colorectal adenocarcinoma with liver-dominant bilobar disease. Diagnosis may be made by histo- or cyto-pathology, or by clinical and imaging criteria.
  3. Disease progression or intolerance to at least two prior Food and Drug Administration-approved therapeutic regimens.
  4. If extrahepatic disease is present, it must be asymptomatic.
  5. If a primary tumor is in place, it must be asymptomatic.
  6. Measurable target tumors using standard imaging techniques (RECIST v. 1.1 criteria).
  7. Tumor replacement < 50% of total liver volume.
  8. Current Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 through screening to first treatment on study.
  9. Completion of prior systemic therapy at least 14 days prior to enrollment.
  10. . Able to understand informed consent.

You CAN'T join if...

  1. At risk of hepatic or renal failure
  2. Serum creatinine > 1.5 mg/dl
  3. Serum bilirubin > 1.3 mg/ml
  4. Albumin < 2.0 g/dL
  5. Aspartate and/or alanine aminotransferase level > 5 times upper normal limit
  6. Any history of hepatic encephalopathy
  7. Cirrhosis or portal hypertension
  8. Clinically evident ascites (trace ascites on imaging is acceptable)
  9. Contraindications to angiography and selective visceral catheterization
  10. Any bleeding diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents (e.g. closure device)
  11. Severe allergy or intolerance to contrast agents, narcotics, or sedatives that cannot be managed medically
  12. Symptomatic lung disease
  13. Prior therapy with Tas-102.
  14. Contraindications to Tas-102
  15. Absolute neutrophil count < 1,500/μl
  16. Platelet count < 75,000/μl
  17. Allergy or intolerance to Tas-102
  18. Unresolved toxicity of greater than or equal to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 2 due to prior therapies.
  19. Evidence of potential delivery of
  20. Greater than 30 Gy absorbed dose of radiation to the lungs during a single 90Y resin microsphere administration; or
  21. Cumulative delivery of radiation to the lungs > 50 Gy over multiple treatments.
  22. Evidence of any detectable Tc-99m macro aggregated albumin flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow.
  23. Previous radiation therapy to the lungs and/or to the upper abdomen
  24. . Any prior arterial liver-directed therapy, including chemoembolization, bland embolization, and 90Y radioembolization
  25. . Any intervention for, or compromise of the ampulla of Vater
  26. . Active uncontrolled infection. Presence of latent or medication-controlled HIV and/or viral hepatitis is allowed.
  27. . Significant extrahepatic disease
  28. Symptomatic extrahepatic disease (including primary tumor, if unresected).
  29. Greater than 10 pulmonary nodules (each < 20 mm in diameter) or combined diameter of all pulmonary nodules > 15 cm.
  30. Peritoneal carcinomatosis
  31. . Life expectancy less than 3 months
  32. . Pregnant or lactating female
  33. . In the investigator's judgment, any co-morbid disease or condition that would place the patient at undue risk and preclude safe use of radioembolization or Tas-102.


  • University of California San Francisco
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Nicholas Fidelman
    Nicholas Fidelman, MD, is a Professor of Clinical Radiology at the University of California, San Francisco and UCSF Mount Zion. Dr. Fidelman received his medical degree from UCSF in 2002, and completed his residency in Diagnostic Radiology from UCSF in 2007, followed by a fellowship in Interventional Radiology from UCSF in 2008.


in progress, not accepting new patients
Start Date
Completion Date
University of California, San Francisco
Phase 1 Research Study
Study Type
At least 21 people participating
Last Updated